On September 9, 2020 Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Biomica, SEP 9, 2020, https://www.prnewswire.com/news-releases/biomica-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126264.html [SID1234564887]). The conference is being held on September 14-16, 2020 virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Elran Haber, CEO of Biomica, will provide an overview of the Company’s business during a live presentation, scheduled for Wednesday, September 16, 12:30 PM (EDT), and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

On September 9, 2020 Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Evogene, SEP 9, 2020, https://www.prnewswire.com/news-releases/evogene-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126266.html [SID1234564885]). The conference is being held on September 14-16, 2020 virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Ofer Haviv, President & CEO of Evogene, will provide an overview of the Company’s business during a live presentation, scheduled for Wednesday, September 16, 12:00 PM (EDT), and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

On September 9, 2020 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that Joseph C. Papa, chairman and CEO; Sam Eldessouky, senior vice president and corporate controller; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020 at 1:15 p.m. ET (Press release, Bausch Health, SEP 9, 2020, View Source [SID1234564883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and audio archive of the events will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: View Source

On September 9, 2020 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the upcoming virtual investor conferences below (Press release, Soligenix, SEP 9, 2020, View Source [SID1234564880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Virtual Global Healthcare Conference on Tuesday, September 15 at 1:20 PM Eastern Time. To view the presentation live, please go to View Source The presentation will be archived there for 90 days. For more information about the Cantor Virtual Global Healthcare Conference, please refer to the conference website at View Source

Lake Street Capital Market’s 4th Annual Best Ideas Growth (BIG4) Conference on September 17, with one-on-one and group meetings throughout the day. For more information about the 4th Annual BIG4 Conference, please refer to the conference website at View Source
For further information regarding Soligenix, Inc., please visit the Company’s website at www.soligenix.com.

On September 9, 2020 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference, being held virtually on September 14-16, 2020 (Press release, Leap Therapeutics, SEP 9, 2020, https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-hc-wainwright-22nd-annual-global-investment-conference-301126144.html [SID1234564878]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leap Presentation Details:

H.C. Wainwright 22nd Annual Global Investment Conference
Date: Wednesday, September 16
Presentation Time: 3:00 p.m. Eastern Time

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.